Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: Enoxaparin vs UFH for VTE Prevention in Acute Ischemic Stroke
NCT00077805Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2003
- Primary completion
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 4 trial of enoxaparin in venous thromboembolism (VTE), sponsored by Sanofi. Started Aug 2003; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00077805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077805.